BioSpace News Archive

NANOBIOTIX announced today that Company management will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Please see below for details of the event.

Encompass Health Corp. (NYSE: EHC) today announced it will participate in the 2024 Leerink Partners Healthcare Crossroads Conference being held in Austin, Texas, May 28-30, 2024.

Newtopia today announced its fourth quarter, fiscal 2023 and first quarter 2024 financial results, operational highlights and filing of its annual financial statements. These results pertain to the three months and year ended December 31, 2023 as well as the three months ended March 31, 2024. All amounts are expressed in Canadian dollars, unless otherwise noted.

Tizona Therapeutics, Inc. announced first-in-human Phase 1b clinical data of TTX-080, a novel, first-in-class, antibody targeting HLA-G, in patients with metastatic colorectal cancer and locally advanced/metastatic head and neck squamous cell carcinoma.

IN8bio, Inc. announced an upcoming presentation of updated results from its fully enrolled Phase 1 study of INB-200 at the 2024 American Society of Clinical Oncology Annual Meeting, to be held May 31st - June 4th in Chicago, Illinois.

Werewolf Therapeutics, Inc. announced the upcoming presentation of clinical data from dose-escalation arms of the Phase 1/1b trial evaluating WTX-124, its conditionally activated Interleukin-2 INDUKINE™ molecule, as monotherapy and in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy.

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the first quarter of 2024 and provided a business update.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit.

Precision Optics Corporation, Inc. today announced that Dr. Joe Forkey, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.